Thomas Burns
Patrimonio netto: 2 M $ in data 31/05/2026
Patrimonio netto: 2 M $ in data 31/05/2026
Thomas M.
Burns is currently a Non-Executive Director at LAVA Therapeutics NV since 2025.
Formerly, Mr. Burns was an Independent Director at Acorda Therapeutics, Inc. from 2023 to 2024 and served as Chief Financial Officer & Senior VP-Finance at XOMA Royalty Corp.
from 2015 to 2026.
Education includes an MBA from Golden Gate University conferred in 1999 and an undergraduate degree from Santa Clara University conferred in 1995.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 25/03/2026 | 36.209 ( 0,29% ) | 2 M $ | 31/05/2026 | |
| 19/09/2025 | 2.000 ( 0,2% ) | 50 910 $ | 31/05/2026 | |
| 19/09/2025 | 2.000 ( 0,11% ) | 50 680 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Direttore/Membro del Consiglio | 07/11/2025 |
| Società | Posizione | Fine |
|---|---|---|
| XOMA ROYALTY CORPORATION | Direttore Finanziario/CFO | 12/01/2026 |
| ACORDA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 21/08/2024 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
XOMA Royalty Corp.
XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops, manufactures and markets therapeutic products for neurological disorders | Health Technology |
Golden Gate University
Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santa Clara University
Santa Clara University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LAVA Therapeutics NV
LAVA Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops antibodies for the treatment of cancer | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale